Report on first half 2013

Lainate

July 31, 2013

1

2

Safe Harbour Statement

This presentation may include forward-looking statements that are based on our management’s beliefs

and assumptions and on information currently available to our management.

The inclusion of forward-looking statements should not be regarded as a representation by Cosmo that

any of its plans will be achieved. Actual results may differ materially from those set forth in this

presentation due to the risks and uncertainties inherent in Cosmo’s ability to develop and expand its

business, successfully complete development of its current product candidates and current and future

collaborations for the development and commercialisation of its product candidates and reduce costs

(including staff costs), the market for drugs to treat IBD diseases, Cosmo’s anticipated future revenues,

capital expenditures and financial resources and other similar statements, may be "forward-looking" and

as such involve risks and uncertainties and risks related to the collaboration between Partners and Cosmo,

including the potential for delays in the development programs for Budesonide MMX®, Rifamycin SV

MMX®, Methylene Blue MMX® and CB-03-01 . No assurance can be given that the results anticipated in

such forward looking statements will occur. Actual events or results may differ materially from Cosmo’s

expectations due to factors which include, but are not limited to, increased competition, Cosmo’s ability to

finance expansion plans, the results of Cosmo’s research and development activities, the success of

Cosmo’s products, regulatory, legislative and judicial developments or changes in market and/or overall

economic conditions. Cosmo assumes no responsibility to update forward-looking statements or to adapt

them to future events or developments.

You are cautioned not to place reliance on these forward-looking statements, which speak only as of the

date hereof, and Cosmo undertakes no obligation to revise or update this presentation.

3

Agenda

• Introduction and H1 2013 highlights Mauro Ajani, CEO

• H1 2013 Financial review Chris Tanner, CFO

• Pipeline update Luigi Moro, CSO

• 2013 Outlook Mauro Ajani, CEO

• Questions & Answers All

4 4

• Approval of Uceris® in the USA in January and launch in February

• Approval of Cortiment® in Holland in January

• Agreement of FDA to phase III clinical trial protocol for CB-17-01 Methylene Blue MMX®

• Indian Authorities allow continuation of Rifamycin SV MMX® phase III trials in India

• CB-03-01 clinical trails progressing as planned

• Sale of 4’885’500 SNTS shares generating a net profit of € 58.2 million

• Lialda® market share continued improving

• COPN will be included in the SXI Life Sciences Index as of September 23

H1 2013 Highlights

5

Income Statement and Statement of Comprehensive Income EUR/1,000 30.06.2013 30.06.2012

Revenues 26,562 40,732

Other Income 15 35

Cost of sales (9,519) (7,759)

Research and development costs (5,791) (4,437)

Selling, general and administrative costs (4,575) (3,399)

Net Operating expenses (19,870) (15,560)

Operating Result 6,692 25,172

Financial income 58,542 984

Financial expenses (365) (263)

Profit Before Taxes 64,869 25,893

Income tax expenses (1,530) (7,188)

Profit For The Period 63,339 18,705

EUR/1,000 30.06.2013 30.06.2012

Profit (loss) for the period (A) 63,339 18,705

Gains/(Losses) on fair value of available for sale financial assets (8,772) 23,500

Gains/(Losses) on cash flow hedge reclassified to profit or loss 14 (12)

Income tax relating to components of other comprehensive income 1 (2)

Total other comprehensive income, net of tax (B) (8,758) 23,486

Total comprehensive income (A)+(B) 54,581 42,190

6

Discussion of income statement H2 2013

• Overall operating revenues declined by 34.8% to € 26.6 million

• Royalties increased by 30.9% to € 7.3 million

• Lialda royalties increased 6.0% to € 5.8 million

• First time Uceris royalties reached € 1.4 million

• MMX Manufacturing increased by 9.8% to € 8.4 million

• Lialda manufacturing revenue declined by 6.8% to € 7.2 million

• First time Uceris manufacturing revenue reached € 1.3 million

• Contract drug manufacturing increased by 2.3% to € 5.4 million

• One time license fees and milestones decreased by 76.1% to € 5.2 million

• Last year there were two milestone payments (one for Uceris of $ 4 m and one for CB-03-01 of $ 25 m) this year there was only one, $ 7 million for Uceris

7

Discussion of income statement H2 2013

• Operating costs increased by 27.7% to € 19.9 million

• COGS increased by 22.7% to € 9.5 million

• SG&A increased by 34.6% to € 4.6 million

• R&D expenditures increased by 30.5% to € 5.8 million

• Higher raw material and consumables cost due to increased activity

• No change in personnel but payment of one time Uceris success bonus to all employees of € 1.7 million

• Payment of facility fee to FDA to qualify as manufacturer of generics

• Increase of amortization and depreciation because of higher property, plant and equipment due to Cristoforo Colombo Real Estate purchase and because first time write off capitalized Budesonide R&D

8

Discussion of income statement H2 2013

• EBITDA declined from € 26.3 million to € 9.4 million

• Financial gain of € 58.2 million on sale of 4’885’500 SNTS shares

• Gross proceeds reached $ 89.2 million or € 69.3 million, the net realized gain amounted to € 58.2 million

• Net profit increased from € 18.7 million to € 63.4 million

• Comprehensive Income increased by 29.4% to € 54.6 million

9

Consolidated Statement of Financial Position

EUR/1,000 30.06.2013 31.12.2012

Financial assets available for sale 51,231 66,070

Other non current assets 44,754 45,795

Cash and cash equivalents 95,149 27,302

Other current assets 16,204 12,678

Total assets 207,338 151,845

Medium-to long-term interest-bearing loans and borrowings

10,924 11,040

Other non-current liabilities 3,703 3,825

Short-term interest-bearing loans and borrowings

1,729 1,797

Other current liabilities 8,653 10,582

Equity attributable to owners of the company 182,168 124,391

Non controlling interest 161 210

Total equity and liabilities 207,338 151,845

10

Discussion of Statement of Financial Position I

• Cash and Cash equivalents increased by € 67.8 m to € 95.1 m

• Good will and intangible assets decreased by 4.5% to € 21.3 million because amortization of capitalized Budesonide R&D started

• Financial assets available for sale decreased by 22.5% or € 26.5 m to € 51.2 m because the number of SNTS shares declined by 4’887’500 or 38% to 2’991’044 SNTS shares. The value of each share increased from $ 10.98 to $ 21.05 per 28.6

11

Discussion of Statement of Financial Position II

• Short term loans declined by 3.8% to € 1.7 million

• Primarily subsidized loans

• Medium term loans and borrowings declined by 1.1% to € 10.9 million

• Came along with Cristoforo Colombo Real estate acquisition

• Equity attributable to owners of the company increased by €57.8 m to €182.2 m

• 14’995’743 shares issued

• 816’227 treasury shares in books, purchased at € 16.56

• 177’622 treasury shares were used to fulfil ESOP obligations

• 87.9% of total Assets financed by Equity

12

1H 2013 Cash Flow

Cash at the end of the period 95,149

Transaction with treasury shares 3,173

Additional investment in Cosmo R&D interests (35)

Loan repayment (net of increase) (192)

Disposal of financial assets 66,839

Investment in fixed assets (net) (1,345)

Investment in intangibles assets (444)

Investment in financial assets available for sales (2,594)

Change in working capital (1,644)

Accrual/payment of employee benefits, other provision and taxes 1,052

Income taxes paid (6,329)

Other non cash items 17

Financial gain on sale of financial assets available for sale (Santarus shares) (58,178)

Depreciation and amortization 2,658

Profit before taxes 64,869

Cash at the beginning of the period 27,302

(60,000) (40,000) (20,000) 0 20,000 40,000 60,000 80,000 100,000

13

Pipeline Update

Product and Indication Drug type Phase I Phase II Phase III MA Launch Partner

Lialda ®/ Mezavant ®/Mesavancol®

Mild to moderate Ulcerative Colitis

5-ASA Giuliani-Shire

Zacol NMX®

Intestinal Disorders (nutraceutical)

Dietary supplement

Dr. Falk

Uceris/Cortiment

Mild to moderate Ulcerative Colitis

Cortico-steroid

Santarus- USA

Ferring – Worldwide (excluding Japan & USA)

Rifamycin SV MMX®

-Travellers’ Diarrhoea

-Uncomplicated diverticulitis

Antibiotic

Santarus - USA

Dr. Falk – Europe & Australia

(excluding Italy)

CB-17-01

- Chromendoscopy for colorectal

cancer prevention in surveillance

patients

- Chromoendoscopy for colorectal

cancer prevention in UC patients

Diagnostic

CB-03-01 (NCE)

Acne

Steroid ester, androgen antagonist

Licensed out world wide

Medicis/Valeant

CB-03-01 (NCE)

Alopecia

Steroid ester, androgen antagonist

Licensed out world wide

Medicis/ Valeant

LMW Heparin MMX®

- Induction of remission in UC

- Maintenance of remission in UC

Biologic

CB-01-16

Opioid Induced Constipation

Opioids Antagonist

Italy Eastern Europe

USA

EU

EU

Q3 HOLLAND CORTIMENT

USA

UCERIS

EU

15 15

Lialda®

• Legal

• On May 9, Shire announced it prevailed in the patent infringement case against Actavis. Acatavis is appealing

• Net Sales

• H1 2013: $ 238 m (+29.3%)

• Cosmo Income

• H1 2013: € 13.0 m (-1.6%) (€ 5.8 m royalties, € 7.2 m manufacturing)

15

16

Budesonide MMX; Uceris® & Cortiment®

• Uceris approved in January and launched on February

• Q1 TRX: 2’200; Q1 Revenue: USD 6.6 million

• Q2 TRX: 11’528 Q2 Revenue: to be announced August 6

• Cosmo Revenue:

• Milestone: USD 7 million

• Manufacturing revenue: USD 1.3 million

• Royalties: USD 1.4 million (assumption revenues of USD 15 m for H1)

• Cortiment approved in January for the Netherlands

• Launch expected in Q4 2013

• Marketing authorization transferred to Ferring

• MRP to be filed

• Next approvals to be expected beginning 2014

16

17 17

Rifamycin SV MMX®

• Regulatory status • Indian Authorities approved continuation of Infectious Diarrhoea phase III clinical

trial by licensee Dr. Falk Pharma

• Number of patients

• 250 patients still need to be recruited for a 3-5 days treatment

• Timing • Trial to start after the monsoon ends in September

17

18

CB-03-01:anti adrogen for topical applications

• Phase II for acne ongoing • Second cohort of 90 patients concluded

• Recruitment of third cohort underway

• Phase I alopecia • Completion of toxicological studies ongoing

• Phase I PK ongoing (treatment completed)

19

CB-17-01 Methylene Blue MMX for colon cancer diagnosis

• Phase II clinical trial for patients with long standing UC completed

• SPA filed and Phase III protocol agreed with FDA

• Protocol subsequently submitted and currently under evaluation by EMA

• CROs selected, sites selected, investigator meetings determined

• First treatment in US projected for early Q4

• First treatment for EU projected for later Q4

20

Outlook for 2013

• Continued growth in royalties and manufacturing revenues

• Strong growth in Uceris expected

• Launch in Cortiment expected

• Lialda to continue gaining market share

• Start of phase III in Methylene Blue MMX in USA and EU

• Re start of Rifamycin SV MMX phase III in India

21

Cosmo Pharmaceuticals

Information Contacts

• Half-Year Report 2013: 31 July 2013

• Number of shares: 14,995,743

• Listing: SIX Swiss exchange, Main board

• ISIN: IT0004167463

• Mauro Ajani, CEO majani@cosmopharma.com

• Chris Tanner, CFO ctanner@cosmopharma.com ph: +39-02-9333’7276

• Giuseppe Cipriano, COO gcipriano@cosmopharma.com

• Luigi Moro, CSO lmoro@cosmopharma.com